Navigation Links
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president for regulatory affairs.

"Over the last 12 years, Eric has played an integral role in clinical stage product partnerships involving major pharmaceutical and biotech companies and leading academic cancer centers and Debbie has been involved in the development of Avastin and Omnitarg, among other key oncology products, at Genentech," said G. Kirk Raab, acting chief executive officer and chairman of BiPar. "Their strong track records of success and experience will help as we begin Phase 2 testing of our promising lead compound, BSI-201, in three major cancers later this year and bring two more oncology compounds into the clinic next year."

BiPar is developing multiple compounds designed to inhibit PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to cell repair and upregulated in certain tumors.

Mr. Malek joins BiPar after seven years at Allos Therapeutics where, as vice president of corporate development, he played a pivotal role in shifting Allos' strategy to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held business development positions at Gilead Sciences, Inc., NeXstar Pharmaceuticals, Ilex Oncology, Inc. and Research Corporation Technologies. He has an undergraduate degree in biochemistry from the University of Arizona and an M.B.A. from the University of Michigan Business School.

Dr. Thomas worked at Genentech, Inc. for almost 17 years, most recently as a senior director of clinical regulatory affairs, where she oversaw products moving from late-stage research and development into Phase 1 clinical testing. Before that, she served as a team leader for Avastin, Omnitarg and Rapitva in the product portfolio management department. Prior to joining Genentech, Dr. Thomas began her career in the pharmaceutical industry as a toxicologist at Syntex Research. Dr. Thomas received her Ph.D. in toxicology and her B.S. in microbiology from the University of Kentucky.

About BiPar Sciences

BiPar Sciences Inc. ( is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients. The Company's lead product candidate is BSI-201, which is now in early-stage clinical testing for advanced malignancies. The Company will be evaluating the potential of BSI-201 in multiple cancers and expects to file investigational new drug applications on as many as two additional cancer drug candidates in early 2008.

SOURCE BiPar Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Choosing Lab Quality Management Software
3. Optimizing Quality Control Data Management
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Monitoring Patient Glucose Levels: New Advances in software make it easier
10. New Advances in Gastric Diagnostics: Smaller is Better
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):